Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lumiradx Ltd (NQ: LMDX )

0.6100 -0.1300 (-17.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 515,210
Open 0.7200
Bid (Size) 0.6100 (1)
Ask (Size) 0.6400 (4)
Prev. Close 0.7400
Today's Range 0.5900 - 0.7633
52wk Range 0.5900 - 8.260
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
From LumiraDx Inc
Via Globe NewsWire
Earnings Scheduled For March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga

Performance

YTD
-31.46%
-31.46%
1 Month
-47.86%
-47.86%
3 Month
-28.24%
-28.24%
6 Month
-42.45%
-42.45%
1 Year
-92.14%
-92.14%

More News

Read More
Earnings Outlook For LumiraDx
Via Benzinga
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
From LumiraDx Inc
Via Globe NewsWire
LumiraDx to Present at Raymond James Institutional Investors Conference
From LumiraDx Inc
Via Globe NewsWire
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
From LumiraDx Inc
Via Globe NewsWire
Catalent, Faraday Future Intelligent Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
From LumiraDx Inc
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
From LumiraDx Inc
Via Globe NewsWire
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
From LumiraDx Inc
Via Globe NewsWire
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
From LumiraDx Inc
Via Globe NewsWire
Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
From LumiraDx Inc
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Walt Disney And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Via Benzinga
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
From LumiraDx Inc
Via Globe NewsWire
LumiraDx Reports Third Quarter 2022 Results
From LumiraDx Inc
Via Globe NewsWire
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
From LumiraDx Inc
Via Globe NewsWire
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.